Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection

BACKGROUND: HCV direct-acting antivirals (DAAs) are produced in India at low cost. However, concerns surrounding reinfection and budgetary impact limit treatment scale-up in India. We evaluate the cost-effectiveness and budgetary impact of HCV treatment in India, including reinfection. METHODS: A cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Chaillon, Antoine, Mehta, Sanjay R., Hoenigl, Martin, Solomon, Sunil S., Vickerman, Peter, Hickman, Matthew, Skaathun, Britt, Martin, Natasha K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553784/
https://www.ncbi.nlm.nih.gov/pubmed/31170246
http://dx.doi.org/10.1371/journal.pone.0217964

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553784/
https://www.ncbi.nlm.nih.gov/pubmed/31170246
http://dx.doi.org/10.1371/journal.pone.0217964

Ejemplares similares